5ANW

MTH1 in complex with compound 24


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.37 Å
  • R-Value Free: 0.225 
  • R-Value Work: 0.199 
  • R-Value Observed: 0.200 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Potent and Selective Inhibitors of Mth1 Probe its Role in Cancer Cell Survival.

Kettle, J.G.Alwan, H.Bista, M.Breed, J.Davies, N.L.Eckersley, K.Fillery, S.Foote, K.M.Goodwin, L.Jones, D.R.Kack, H.Lau, A.Nissink, J.W.Read, J.Scott, J.S.Taylor, B.Walker, G.Wissler, L.Wylot, M.

(2016) J Med Chem 59: 2346

  • DOI: https://doi.org/10.1021/acs.jmedchem.5b01760
  • Primary Citation of Related Structures:  
    5ANS, 5ANT, 5ANU, 5ANV, 5ANW

  • PubMed Abstract: 

    Recent literature has claimed that inhibition of the enzyme MTH1 can eradicate cancer. MTH1 is one of the "housekeeping" enzymes that are responsible for hydrolyzing damaged nucleotides in cells and thus prevent them from being incorporated into DNA. We have developed orthogonal and chemically distinct tool compounds to those published in the literature to allow us to test the hypothesis that inhibition of MTH1 has wide applicability in the treatment of cancer. Here we present the work that led to the discovery of three structurally different series of MTH1 inhibitors with excellent potency, selectivity, and proven target engagement in cells. None of these compounds elicited the reported cellular phenotype, and additional siRNA and CRISPR experiments further support these observations. Critically, the difference between the responses of our highly selective inhibitors and published tool compounds suggests that the effect reported for the latter may be due to off-target cytotoxic effects. As a result, we conclude that the role of MTH1 in carcinogenesis and utility of its inhibition is yet to be established.


  • Organizational Affiliation

    Oncology Innovative Medicines Unit, AstraZeneca , 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE158Homo sapiensMutation(s): 0 
EC: 3.6.1.55 (PDB Primary Data), 3.6.1.56 (PDB Primary Data)
UniProt & NIH Common Fund Data Resources
Find proteins for P36639 (Homo sapiens)
Explore P36639 
Go to UniProtKB:  P36639
PHAROS:  P36639
GTEx:  ENSG00000106268 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP36639
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
9CQ
Query on 9CQ

Download Ideal Coordinates CCD File 
B [auth A]2-[4-(2-AMINOQUINAZOLIN-4-YL)PHENYL]-N,N-DIMETHYL-ACETAMIDE
C18 H18 N4 O
IYSIGMIQNYJRNC-UHFFFAOYSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
9CQ Binding MOAD:  5ANW Kd: 3 (nM) from 1 assay(s)
BindingDB:  5ANW IC50: 9 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.37 Å
  • R-Value Free: 0.225 
  • R-Value Work: 0.199 
  • R-Value Observed: 0.200 
  • Space Group: P 21 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 61.13α = 90
b = 66.07β = 90
c = 35.98γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
MOSFLMdata reduction
Aimlessdata scaling
AMoREphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2016-03-02
    Type: Initial release
  • Version 1.1: 2016-03-16
    Changes: Atomic model
  • Version 1.2: 2016-04-06
    Changes: Database references